Hosted on MSN5m
Lilly's Zepbound approved by FDA for sleep apnea treatment
The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...
Lilly seeking to join lawsuit over compounded GLP-1 drugs
Eli Lilly (NYSE:LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination ...
devdiscourse40m
China's New Mental Health Initiative Targets Youth and Innovation
China's National Health Commission plans to address gaps in mental health services from 2025-2027, focusing on youth. Eli ...